AKT1 and bladder transitional cell carcinoma: For instance, paclitaxel upregulates the expression of miR-143, which post-transcriptionally suppresses the expression of AKT.[60] The paclitaxel-combination therapy, including carboplatin, exhibits a response rate of 14% to 65% in advanced urothelial carcinoma and is particularly suitable for patients with renal insufficiency.[61] In our study, we observed that the IC50 values of 6 drugs – imatinib, docetaxel, dasatinib, cisplatin, NVP-BEZ235, and paclitaxel – were relatively low in the context of high-risk BLCA, suggesting a heightened sensitivity of the cancer to these agents.